Lipocine’s (LPCN) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Monday, Marketbeat.com reports.

LPCN has been the subject of a number of other research reports. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.00.

Lipocine Price Performance

NASDAQ LPCN opened at $1.94 on Monday. Lipocine has a 12 month low of $1.81 and a 12 month high of $12.37. The company has a 50-day moving average of $8.10 and a 200-day moving average of $5.78. The company has a market cap of $14.16 million, a P/E ratio of -1.15 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%. The company had revenue of $1.15 million during the quarter, compared to the consensus estimate of $0.12 million.

Insider Buying and Selling

In other Lipocine news, CEO Mahesh V. Patel bought 25,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average price of $2.03 per share, with a total value of $50,750.00. Following the transaction, the chief executive officer owned 160,679 shares in the company, valued at $326,178.37. This trade represents a 18.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John W. Higuchi bought 123,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were acquired at an average cost of $2.05 per share, with a total value of $252,150.00. Following the transaction, the director owned 163,797 shares in the company, valued at approximately $335,783.85. This represents a 301.49% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 173,000 shares of company stock valued at $353,400. Corporate insiders own 6.35% of the company’s stock.

Institutional Trading of Lipocine

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new position in Lipocine in the 3rd quarter worth approximately $41,000. Jane Street Group LLC purchased a new position in Lipocine in the 4th quarter worth approximately $85,000. Renaissance Technologies LLC boosted its holdings in Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after acquiring an additional 1,300 shares during the period. Boothbay Fund Management LLC purchased a new position in Lipocine in the 4th quarter worth approximately $441,000. Finally, Geode Capital Management LLC boosted its holdings in Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after acquiring an additional 1,374 shares during the period. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.